news & publications
news
Pharvaris Announces $80 Million Series C Financing to Advance Novel Oral Bradykinin-B2-Receptor Antagonists for the Treatment of HAE
New investors include Viking Global Investors, General Atlantic, and Cormorant Asset Management, with an expanded position by Venrock Healthcare Capital Partners Phase 2 study of PHVS416 expected to initiate in 2021 Zug, Switzerland, Nov. 18, 2020 – Pharvaris, a...
Pharvaris Presents Clinical Data at ACAAI 2020 Demonstrating Safety and Therapeutic Potential of Oral PHA121 for the Treatment of HAE
PHA121 outperforms icatibant in a bradykinin-challenge study Zug, Switzerland, Nov. 13, 2020 – Pharvaris, a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema...
Preclinical Characterization of Novel B2-Receptor Antagonists Published in Frontiers in Pharmacology
Data further validate Pharvaris’ B2-receptor-antagonist program Zug, Switzerland, July 30, 2020 – Pharvaris, a clinical-stage company focused on the discovery and development of novel oral B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and...
PHA121, the first orally available bradykinin B2-receptor antagonist, shows clinically relevant activity in a translational in vivo model
Data accepted for presentation at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2020 Zug, Switzerland, April 9, 2020 – Pharvaris GmbH, a clinical-stage company focused on the discovery and development of novel oral B2-receptor...
Pharvaris Appoints Peng Lu, M.D., Ph.D., as Chief Medical Officer
Company strengthens executive team with addition of skilled HAE drug developer Leiden, The Netherlands, Feb. 7, 2020 – Pharvaris B.V., a clinical-stage company focused on the discovery and development of novel oral B2-receptor antagonists for the treatment of...
Pharvaris Announces $66 Million Series B Financing to Advance the Clinical Development of an Oral Therapy for Hereditary Angioedema
Pharvaris has initiated its first-in-human clinical trial of PHA121 Series B participants led by Foresite Capital with additional new investors Bain Capital Life Sciences, venBio Partners, and Venrock Partners Leiden, The Netherlands, Sept. 10, 2019 – Pharvaris B.V.,...